Agilon Health (AGL) to Release Earnings on Wednesday

Agilon Health (NYSE:AGL) is expected to release its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect Agilon Health to post earnings of ($0.27) per share and revenue of $1.4614 billion for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

Agilon Health Stock Performance

Agilon Health stock opened at $0.43 on Tuesday. Agilon Health has a one year low of $0.34 and a one year high of $6.08. The company has a 50-day simple moving average of $0.73 and a 200-day simple moving average of $0.86. The firm has a market capitalization of $180.05 million, a P/E ratio of -0.58 and a beta of 0.06.

Wall Street Analysts Forecast Growth

Several research firms have commented on AGL. Barclays decreased their target price on shares of Agilon Health from $1.50 to $1.00 and set an “underweight” rating for the company in a research report on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Agilon Health in a research note on Wednesday, January 21st. Wells Fargo & Company reduced their price target on Agilon Health from $1.50 to $1.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Royal Bank Of Canada raised Agilon Health from a “hold” rating to a “moderate buy” rating in a report on Wednesday, December 3rd. Finally, BTIG Research restated a “neutral” rating on shares of Agilon Health in a research note on Friday, December 12th. Four investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Agilon Health currently has a consensus rating of “Hold” and an average price target of $2.71.

Institutional Trading of Agilon Health

A number of hedge funds and other institutional investors have recently modified their holdings of AGL. Goldman Sachs Group Inc. lifted its holdings in shares of Agilon Health by 196.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 20,055,214 shares of the company’s stock valued at $13,812,000 after buying an additional 13,283,930 shares during the period. AQR Capital Management LLC raised its position in Agilon Health by 1,346.6% in the fourth quarter. AQR Capital Management LLC now owns 10,211,767 shares of the company’s stock worth $7,033,000 after acquiring an additional 9,505,837 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Agilon Health by 30.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 8,019,002 shares of the company’s stock worth $5,523,000 after acquiring an additional 1,893,434 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Agilon Health by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 7,177,477 shares of the company’s stock valued at $4,944,000 after acquiring an additional 35,054 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in shares of Agilon Health by 41.3% during the 3rd quarter. Bank of America Corp DE now owns 5,414,614 shares of the company’s stock valued at $5,577,000 after purchasing an additional 1,581,284 shares in the last quarter.

Agilon Health Company Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.